Chugai Pharmaceutical Co., Ltd.
CHGCF
$47.72
$1.312.82%
OTC PK
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.84B | 1.74B | 1.70B | 1.62B | 1.38B |
| Total Other Revenue | 409.33M | 265.09M | 188.57M | 357.35M | 218.73M |
| Total Revenue | 2.25B | 2.01B | 1.89B | 1.98B | 1.60B |
| Cost of Revenue | 568.15M | 609.76M | 576.28M | 618.35M | 491.44M |
| Gross Profit | 1.68B | 1.40B | 1.32B | 1.36B | 1.10B |
| SG&A Expenses | 239.60M | 196.71M | 152.48M | 212.57M | 152.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 2.63M | -61.14M | -1.17M | -1.80M | 1.25M |
| Total Operating Expenses | 1.15B | 1.06B | 996.14M | 1.17B | 923.43M |
| Operating Income | 1.10B | 946.41M | 896.67M | 809.16M | 672.81M |
| Income Before Tax | 1.10B | 941.63M | 891.28M | 822.97M | 672.91M |
| Income Tax Expenses | 269.25M | 268.96M | 253.25M | 222.60M | 171.70M |
| Earnings from Continuing Operations | 833.22M | 672.67M | 638.03M | 600.37M | 501.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 833.22M | 672.67M | 638.03M | 600.37M | 501.21M |
| EBIT | 1.10B | 946.41M | 896.67M | 809.16M | 672.81M |
| EBITDA | 1.30B | 949.18M | 899.30M | 1.01B | 675.50M |
| EPS Basic | 0.51 | 0.41 | 0.39 | 0.36 | 0.30 |
| Normalized Basic EPS | 0.42 | 0.36 | -- | 0.31 | 0.26 |
| EPS Diluted | 0.51 | 0.41 | 0.39 | 0.36 | 0.30 |
| Normalized Diluted EPS | 0.42 | 0.36 | -- | 0.31 | 0.26 |
| Average Basic Shares Outstanding | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B |
| Average Diluted Shares Outstanding | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B |
| Dividend Per Share | 0.47 | 0.35 | -- | 0.37 | -- |
| Payout Ratio | -- | 0.45% | -- | 0.32% | 87.31% |